CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the presentatio ...

CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, February 26, 2026, to review the company’s fourth quarter and full year 2025 financial results and provide business updates. The webcast and conference call may be accessed by visiting “Investor Events” on the investors sec ...

Core Insights - Wave Life Sciences has regained full rights to WVE-006, an investigational RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD), from GSK, allowing the company to advance its development strategy independently [1][2] - The company plans to engage with the FDA regarding a potential accelerated approval pathway for WVE-006, with regulatory feedback expected by mid-2026 [1][2] - Wave anticipates data from the 400 mg multidose cohort of the RestorAATion-2 clinical trial in the first quarter of 2026, with additional data from the 600 mg cohorts expected later in 2026 [1][2] Company Developments - Wave Life Sciences is focused on RNA medicines and has a diversified pipeline that includes clinical programs for AATD, obesity, Duchenne muscular dystrophy, and Huntington's disease [6] - The company has a strong cash runway, expecting to fund operations into the third quarter of 2028, not including potential future milestone payments from its collaboration with GSK [4] - Wave's collaboration with GSK continues to expand, with a fourth program selected for advancement, potentially leading to up to $2.8 billion in milestone payments and tiered royalties [3] Clinical Trial Progress - WVE-006 has shown promising interim data, achieving key treatment goals for AATD, including significant AAT production during acute phase response [2] - The ongoing RestorAATion-2 clinical trial is on track, with data from the 400 mg cohort expected in early 2026 and further data from the 600 mg cohort anticipated later that year [1][2]

Wave Life Sciences FY Conference Summary Company Overview - **Company**: Wave Life Sciences (NasdaqGM: WVE) - **Industry**: RNA Medicines and Biotechnology Key Points and Arguments RNA Medicines Potential - Wave Life Sciences aims to unlock the potential of RNA medicines to transform human health, emphasizing the foundational role of their proprietary RNA chemistry [2][3] Clinical Portfolio and Innovations - The company has developed a proprietary chemistry engine that allows rapid translation of genetic insights into medicines, exemplified by their obesity therapy, which progressed from mouse data to human clinical data in 18 months [3] - The dominant program discussed is the GalNAc-conjugated INHBE siRNA program, which shows promise in treating obesity by improving body composition through fat reduction while preserving muscle mass [4][11] Manufacturing and Financial Position - Wave Life Sciences has in-house GMP manufacturing capabilities, enabling rapid advancement of their clinical programs [4] - The company entered 2026 with $602 million in cash, sufficient to fund operations into Q3 2028 [5] Clinical Data and Efficacy - The INHBE program has shown a reduction in fat mass and preservation of lean mass, with a focus on visceral fat reduction, which is critical for cardiovascular health [12][27] - Preclinical data indicated a potent and durable reduction in Activin E levels, leading to significant fat loss and muscle preservation [18][27] Treatment Paradigm Shift - Current obesity treatments, particularly GLP-1s, are limited by muscle mass loss. Wave's approach aims to provide a treatment paradigm shift by preserving muscle while reducing fat, potentially allowing for less frequent dosing (once or twice a year) [11][12][20] Future Clinical Studies - The company plans to accelerate the development of WVE-007 in obesity and initiate new clinical studies, including combination and maintenance studies [10][32] - The Phase 2A portion of the INLIGHT study will explore the effects of INHBE in patients with higher BMI and comorbidities [10][32] RNA Editing Programs - Wave Life Sciences is advancing its RNA editing programs, particularly for Alpha-1 Antitrypsin Deficiency (AATD) and PNPLA3-related liver disease, with a focus on correcting genetic mutations to restore protein function [35][41] - The AATD program targets a rare disease affecting approximately 200,000 patients in the US and Europe, with no approved therapies for liver manifestations [35] Bifunctional Constructs - The company is exploring bifunctional conjugates that combine the benefits of RNA editing and siRNA, potentially allowing for a single therapeutic construct that can both silence and upregulate targets [44] Regulatory Pathway and Milestones - Wave Life Sciences is focused on a regulatory pathway that emphasizes body composition changes in obesity studies, with a goal of demonstrating significant fat loss while preserving muscle mass [29][60] - Anticipated milestones include multiple data sets on obesity and updates on RNA editing programs throughout 2026 [44][60] Additional Important Insights - The company emphasizes the importance of body composition in obesity treatment, highlighting the need for therapies that not only reduce weight but also improve metabolic health by targeting visceral fat [12][30] - Wave Life Sciences is positioning itself to address the challenges of long-term adherence to current obesity therapies by offering a more tolerable and effective treatment option [55][58]

Wave Life Sciences J.P. Morgan Healthcare Conference January 13, 2026 Forward-looking statements Translating genetic insights into potentially best-in-class medicines This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulato ...

Core Insights - Wave Life Sciences is advancing its clinical programs, particularly focusing on WVE-007 for obesity and expanding its RNA editing portfolio, with significant milestones expected in 2026 [1][2][10]. Group 1: WVE-007 for Obesity - Wave plans to initiate a Phase 2a multidose portion of the INLIGHT clinical trial for WVE-007 in individuals with obesity and higher BMI in the first half of 2026 [1][10]. - Initial data from a 240 mg single-dose study of WVE-007 showed fat loss comparable to GLP-1 (semaglutide) at three months, with muscle preservation and potential for infrequent dosing [1][3]. - The INLIGHT trial demonstrated sustained suppression of serum Activin E, supporting the feasibility of once or twice yearly dosing [3]. Group 2: RNA Editing Initiatives - Wave has achieved the first successful clinical translation of RNA editing with WVE-006 for alpha-1 antitrypsin deficiency (AATD) and plans to provide updates from the RestorAATion-2 trial in 2026 [1][10]. - The company is advancing WVE-008, targeting nine million individuals with homozygous PNPLA3 I148M liver disease in the U.S. and Europe, with a Clinical Trial Application (CTA) expected in 2026 [1][10]. Group 3: Financial Position - As of December 31, 2025, Wave reported preliminary, unaudited cash and cash equivalents of approximately $602 million, providing a cash runway into the third quarter of 2028 [1][9]. Group 4: Upcoming Events - Wave will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, highlighting its strategic priorities and clinical advancements [1][12].

Core Insights - Wave Life Sciences Ltd. is a clinical-stage biotechnology company focused on RNA medicines to improve human health [1][3] - The company will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 [1] Company Overview - Wave Life Sciences utilizes its PRISM platform, which integrates various modalities and chemistry innovations to develop RNA medicines [3] - The company’s pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [3] - Wave Life Sciences aims to transform human health by addressing both rare and common disorders through its RNA-targeting modalities [3]

Core Viewpoint - Wave Life Sciences Ltd. has announced the pricing of its public offering of ordinary shares and pre-funded warrants, aiming to raise approximately $350 million before expenses [1][2]. Group 1: Offering Details - The public offering consists of 15,789,475 ordinary shares priced at $19.00 each, along with pre-funded warrants for 2,631,578 ordinary shares at an offering price of $18.9999 [1][2]. - The offering is expected to close on or about December 11, 2025, subject to customary closing conditions [2]. Group 2: Underwriters - Jefferies, Leerink Partners, and BofA Securities are acting as joint book-running managers for the offering, while Truist Securities and Mizuho are serving as book-runners [3]. Group 3: Company Overview - Wave Life Sciences is a biotechnology company focused on RNA medicines, utilizing its PRISM® platform to address both rare and common disorders [6]. - The company's pipeline includes clinical programs targeting obesity, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy, and Huntington's disease, along with several preclinical programs [6].

Core Thesis - Wave Life Sciences Ltd. is positioned for significant growth with its RNA-based therapies, particularly WVE-006 and WVE-007, which could reshape its valuation and market profile [2][5][8] Pipeline and Clinical Developments - The near-term focus is on WVE-006, an RNA editing therapy for Alpha-1 Antitrypsin Deficiency (AATD), which has shown promising results in Phase 1b/2a trials, indicating it may become a best-in-class therapy [3][4] - WVE-007, targeting obesity through siRNA therapy, shows potential for transformative treatment, with preclinical data indicating selective fat loss while preserving lean muscle [5][6] Financial Implications - WVE-006 is partnered with GSK, allowing Wave to earn up to $525 million in milestones and high-teens royalties, which will alleviate financing pressure and support further R&D investments [4] - Successful validation of WVE-007 could lead to a stock appreciation of 40% or more, highlighting the company's potential as a rare RNA-based biotech with multiple high-value opportunities [7][8] Market Position and Growth Potential - Additional pipeline candidates, including therapies for Duchenne muscular dystrophy and Huntington's disease, enhance the company's growth prospects, with early-stage data supporting their potential [6] - The combined assets of Wave Life Sciences present a compelling risk/reward profile, with near-term catalysts expected to drive stock appreciation by 10-20% [7]

Core Insights - Wave Life Sciences Ltd. is set to announce interim data from the Phase 1 INLIGHT clinical trial for WVE-007, an investigational treatment for obesity, on December 8, 2025 [1] - The company utilizes its proprietary SpiNA design in the development of WVE-007, which targets INHBE mRNA linked to obesity [3] Group 1: WVE-007 Overview - WVE-007 is a GalNAc-siRNA designed to silence INHBE mRNA, which has shown potential in improving body composition and reducing the risk of type 2 diabetes and cardiovascular disease [3] - Preclinical studies indicate that WVE-007 can lead to adipocyte shrinkage, reduced inflammation, and improved insulin sensitivity [3] - When used in conjunction with semaglutide, WVE-007 demonstrated a doubling of weight loss in mice and prevented weight regain after stopping semaglutide [3] Group 2: INLIGHT Clinical Trial - The INLIGHT trial is a first-in-human study evaluating WVE-007 in adults with overweight or obesity, focusing on safety, tolerability, and various health metrics [4] - The trial employs a 3:1 active to placebo ratio and is being conducted at multiple sites, including locations in the US [4] Group 3: Company Background - Wave Life Sciences is a biotechnology firm dedicated to RNA medicines, with a diverse pipeline addressing conditions such as obesity, alpha-1 antitrypsin deficiency, and Duchenne muscular dystrophy [5] - The company's PRISM® platform integrates various RNA-targeting modalities, enabling innovative treatments for both rare and common diseases [5] - Wave Life Sciences is headquartered in Cambridge, MA, and aims to transform human health through scientific breakthroughs [5]